Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/16156
Full metadata record
DC FieldValueLanguage
dc.contributor.authorĐorović Jovanović, Jelena-
dc.contributor.authorMarković, Zoran-
dc.contributor.authorKokanovic, Mihajlo-
dc.contributor.authorFilipovic, Nenad-
dc.contributor.authorStanojevic Pirkovic, Marijana-
dc.date.accessioned2023-02-08T16:35:58Z-
dc.date.available2023-02-08T16:35:58Z-
dc.date.issued2021-
dc.identifier.issn--
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/16156-
dc.description.abstractHeart failure (HF) is a condition that affects mostly older populations. It can be treated with different medications, and one of them is Entresto. This is a medication which is consisting of two drugs, sacubitril (SAC) and valsartan (VAL). Here, in this study, are performed molecular docking simulations in order to examine the inhibitory potency of SAC and VAL towards neprilysin (NEP) and angiotensin II receptor (AT2), respectively. The achieved thermodynamic parameters shows that SAC and VAL can bind to targeted protein, and inhibit NEP and AT2. The best binding sites are determined. Also, the amino acids responsible for binding are identified.-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.sourceBIBE 2021 - 21st IEEE International Conference on BioInformatics and BioEngineering, Proceedings-
dc.titleInhibitory potency of Valsartan/Sacubitril drug combination: Molecular docking simulations-
dc.typeconferenceObject-
dc.identifier.doi10.1109/BIBE52308.2021.9635185-
dc.identifier.scopus2-s2.0-85123716698-
Appears in Collections:Faculty of Engineering, Kragujevac
Faculty of Medical Sciences, Kragujevac
Institute for Information Technologies, Kragujevac

Page views(s)

1035

Downloads(s)

5

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.